	US 12,291,528 B2
	Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
Benoit Robert, Cambridge, MA (US)
Assigned to Genzyme Corporation, Cambridge, MA (US)
Filed by Genzyme Corporation, Cambridge, MA (US)
Filed on Nov. 9, 2023, as Appl. No. 18/505,713.
Application 18/505,713 is a continuation of application No. 17/985,531, filed on Nov. 11, 2022, granted, now 11,814,383.
Claims priority of application No. 21207942 (EP), filed on Nov. 12, 2021.
Prior Publication US 2024/0150352 A1, May 9, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01)

CPC C07D 471/04 (2013.01) [C07B 2200/13 (2013.01)]

20 Claims

1. A pharmaceutical composition in the form of a liquid suspension, comprising a pharmaceutically acceptable carrier and the compound 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine monohydrate in crystalline form exhibiting an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 14.9±0.2, 20.2±0.2, 20.7±0.2, 21.4±0.2, 25.1±0.2, 28.0±0.2, and 30.0±0.2.